Dharan NJ, et al. - Researchers assessed the role of antiretroviral therapy (ART) in reducing or contributing to liver fibrosis in HIV-infected individuals. For this investigation, they assessed study participants in the Strategic Timing of AntiRetroviral Treatment trial (START) for liver fibrosis using the AST to platelet ratio index (APRI) and Fibrosis-4 Index (FIB-4), and evaluated the potential benefit of early vs delayed ART on liver fibrosis progression. Among ART-naïve, they found that significant liver fibrosis was rare in HIV-positive persons with elevated CD4 counts. Findings suggested that early ART may be beneficial for preventing the development of liver fibrosis.